Clene Inc. signs $7.2 million fourth-year NIH grant subaward amendment with NYU
Clene Inc. entered into a subaward amendment on October 15, 2026, for the fourth year of a four-year $45.1 million NIH grant, with New York University receiving up to $7.2 million for the period September 1, 2026 to August 31, 2027. The grant supports an Expanded Access Program for CNM-Au8 treatment of amyotrophic lateral sclerosis, and the other terms of the subaward remain unchanged. The filing is an administrative funding update under an existing grant rather than a change in the company's financial results or guidance.
Key points
- Subaward amendment dated October 15, 2026, for up to $7.2 million with New York University
- Covers the period September 1, 2026 to August 31, 2027
- Part of a four-year, $45.1 million NIH grant announced October 5, 2023
- Other subaward terms from the March 16, 2026 filing remain in effect
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.